| Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets |
Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced first quarter financial results for 2025 and provided a corporate update. |
prnewswire.com |
2025-05-15 12:05:00 |
Czytaj oryginał (ang.) |
| PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whethe. |
businesswire.com |
2025-05-09 20:00:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets |
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2024 and provided a corporate update. |
prnewswire.com |
2025-03-21 10:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders |
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options. |
accesswire.com |
2024-11-15 10:00:00 |
Czytaj oryginał (ang.) |
| PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whethe. |
businesswire.com |
2024-11-14 20:55:00 |
Czytaj oryginał (ang.) |
| PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger |
WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Pulmatrix, Inc. ("Pulmatrix") (NASDAQ CM:PULM) regarding possible breaches of fiduciary duties and other violations of law related to Pulmatrix's agreement to merge with Cullgen Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pulmatrix-inc. |
accesswire.com |
2024-11-14 19:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM |
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pulmatrix , Inc. (NASDAQ: PULM ), relating to the proposed merger with Cullgen, Inc. Under the terms of the agreement, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. |
globenewswire.com |
2024-11-14 19:13:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders |
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: |
globenewswire.com |
2024-11-14 09:39:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Pulmatrix (Nasdaq: PULM) for possible breaches of fiduciary duty and other violations of law in its transaction with Cullgen. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company, and pre-merger Cullgen. |
businesswire.com |
2024-11-13 23:53:00 |
Czytaj oryginał (ang.) |
| PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Cullgen Inc. is fair to Pulmatrix shareholders. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. Halper Sadeh encourages Pulmatrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or. |
businesswire.com |
2024-11-13 12:25:00 |
Czytaj oryginał (ang.) |
| Pulmatrix and Cullgen Announce Proposed Merger |
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE ™ technology Cullgen and Pulmatrix will host an informational webcast about the proposed merger that will be made available to access at 12:00 pm ET today FRAMINGHAM, Mass. and SAN DIEGO, Calif. |
prnewswire.com |
2024-11-13 11:00:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update |
Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 Completed PUR1900 wind down activities Cash runway projected into Q4 2026 FRAMINGHAM, Mass. , Nov. 8, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2024 and provided a corporate update on its clinical assets. |
prnewswire.com |
2024-11-08 12:26:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update |
Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 FRAMINGHAM, Mass. , Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets. |
prnewswire.com |
2024-08-13 13:05:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation |
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease. |
prnewswire.com |
2024-05-29 12:45:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) |
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE. |
prnewswire.com |
2024-05-15 13:35:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update |
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval outside the United States BEDFORD, Mass. , May 10, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced first quarter financial results for 2024 and provided a corporate update on its development programs. |
prnewswire.com |
2024-05-10 12:05:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update |
2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix BEDFORD, Mass. , March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs. |
prnewswire.com |
2024-03-28 11:05:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives |
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix Pulmatrix to significantly reduce cash burn and focus on strategic alternatives that leverage the company's promising pipeline, iSPERSE™ technology and approximately $19 million cash on hand as of 12/31/23 BEDFORD, Mass. , Jan. 8, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced that it has entered into a further amendment to its agreement with Cipla for the development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA). |
prnewswire.com |
2024-01-08 11:00:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update |
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 2024 Received "study may proceed" letter on an IND for a Phase 2 study of PUR3100 for acute migraine $21.3 million in cash and cash equivalents at the end of Q3 2023 providing projected cash runway into Q1 2025 BEDFORD, Mass. , Nov. 9, 2023 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2023 and provided a corporate update on its development programs. |
prnewswire.com |
2023-11-09 11:05:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine |
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine BEDFORD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 (Dihydroergotamine Mesylate Inhalation Powder) in the Acute Treatment of Migraine. |
prnewswire.com |
2023-09-19 13:05:00 |
Czytaj oryginał (ang.) |
| Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now |
Pulmatrix, Inc. (PULM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2023-09-11 15:16:13 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole |
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma BEDFORD, Mass. , Aug. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology. |
prnewswire.com |
2023-08-23 13:05:00 |
Czytaj oryginał (ang.) |
| Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update |
Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated in Q3 2024 Submitted an IND for a Phase 2 study of PUR3100 for Acute Migraine $25.8 million in cash and cash equivalents at the end of Q2 2023 providing projected cash runway into Q1 2025 BEDFORD, Mass. , Aug. 10, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs. |
prnewswire.com |
2023-08-10 13:05:00 |
Czytaj oryginał (ang.) |